Chipscreen Biosciences, Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shenzhen China (2001)

Organization Overview

First Clinical Trial
2013
NCT01836679
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chipscreen Biosciences, Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Carcinoma (Phase 1)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

HIV Infections (Phase 3)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Ovarian Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial APIs: 28